We are live on ! Find out more
OKYO

OKYO Pharma
OKYO

6 hedge funds and large institutions have $1.02M invested in OKYO Pharma in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.09% less ownership

Funds ownership: 3.04% → 2.95% (-0.09%)

14% less funds holding

Funds holding: 7 → 6 (-1)

16% less capital invested

Capital invested by funds: $1.21M → $1.02M (-$188K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$17.2K

Top Sellers

Rank Fund Capital Flow
1
HSBC Holdings
HSBC Holdings
United Kingdom
-$20.3K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$13.6K
3
UBS Group
UBS Group
Switzerland
-$1.59K

OKYO Hedge Fund Activity: Q3 2024 in Review

6 of the 6,980 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q3 2024, worth a combined $1.02M — down 16% from $1.21M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of OKYO and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $17.2K. The largest seller was HSBC Holdings, exiting entirely with an estimated $20.3K sold.

  • 6 institutional investors held OKYO Pharma (OKYO) as of Q3 2024, down from 7 in Q2 2024.
  • Funds reported $1.02M of OKYO Pharma stock for Q3 2024, down 16% quarter-over-quarter.
  • 1 fund opened new OKYO Pharma positions in Q3 2024 and 2 closed out, a net change of -1 holder.
  • The largest OKYO Pharma buyer in Q3 2024 was Citadel Advisors, an estimated $17.2K added.
  • The largest OKYO Pharma seller in Q3 2024 was HSBC Holdings, an estimated $20.3K sold.

Based on aggregated 13F filings for Q3 2024.